Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 4/20 | 0.60 |
| ▸ | IKBKB | O14920 | 10/20 | 0.52 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.47 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.47 |
| ▸ | CHUK | O15111 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2905622 | 0.90 | FYN (0.72) | FYNIKBKBNTRK1CHUKMAPK10 | |
| Hydrochloric Acid SCHEMBL1202037 | 0.89 | FYN (0.71) | FYNIKBKBNTRK1CHUKMAPK10 | |
| SCHEMBL2905868 | 0.87 | FYN (0.50) | FYNIKBKBNTRK1NTRK3NTRK2 | |
| SCHEMBL1202966 | 0.85 | NTRK1 (0.50) | FYNIKBKBNTRK1HDAC3HDAC1 | |
| SCHEMBL1203218 | 0.85 | NTRK1 (0.49) | FYNIKBKBNTRK1HDAC3HDAC1 | |
| SCHEMBL1202088 | 0.84 | FYN (0.63) | FYNNTRK1NTRK3NTRK2PIM1 | |
| SCHEMBL1203601 | 0.84 | BRAF (0.51) | FYNIKBKBNTRK1HDAC3HDAC1 | |
| SCHEMBL2905633 | 0.82 | HDAC3 (0.46) | FYNIKBKBHDAC3HDAC1HDAC2 | |
| SCHEMBL2902453 | 0.81 | PIM1 (0.61) | FYNIKBKBNTRK1NTRK3NTRK2 | |
| SCHEMBL1202134 | 0.81 | IKBKB (0.65) | FYNIKBKBNTRK1CHUKMAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046127-A1 | Imidazopyridazines for Use as Protein Kinase Inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2011-02-24 | — | — | US | disclosed |
| EP-2217601-A1 | IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS | Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009060197-A1 | IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046127-A1 | Imidazopyridazines for Use as Protein Kinase Inhibitors | PIM1, PIM3, PIM2 | FYN 403/4885IKBKB 297/4885NTRK1 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.